(Q46799053)

25 December 2017

title

D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients (English)

1 reference

25 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Leguay T

1

1 reference

25 December 2017

Desplat V

series ordinal

2

1 reference

25 December 2017

Marit G

series ordinal

3

1 reference

25 December 2017

Mahon FX

series ordinal

4

1 reference

25 December 2017

publication date

1 December 2005

1 reference

25 December 2017

published in

Leukemia

1 reference

25 December 2017

volume

19

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

page(s)

2332-3; author reply 2333-4

1 reference

25 December 2017

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403993

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403993

1 reference

25 December 2017

1 reference

25 December 2017